donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data

INDP Indaptus Therapeutics

2.340
+0.230+10.90%
Close 06/28 16:00 ET
2.390
+0.05+2.14%
Post Mkt Price 06/28 16:10 ET
High
2.406
Open
2.120
Turnover
256.66K
Low
2.090
Pre Close
2.110
Volume
115.21K
Market Cap
19.33M
P/E(TTM)
Loss
52wk High
28.830
Shares
8.26M
P/E(Static)
Loss
52wk Low
1.890
Float Cap
11.66M
Bid/Ask %
-90.00%
Historical High
24760.000
Shs Float
4.98M
Volume Ratio
2.64
Historical Low
1.890
Dividend TTM
--
Div Yield TTM
--
P/B
0.58
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
2.31%
Amplitude
14.97%
Avg Price
2.227
Lot Size
1
Float Cap
11.66M
Bid/Ask %
-90.00%
Historical High
24760.000
Shs Float
4.98M
Volume Ratio
2.64
Historical Low
1.890
Dividend TTM
--
P/B
0.58
Dividend LFY
--
Turnover Ratio
2.31%
Amplitude
14.97%
Avg Price
2.227
Lot Size
1
Price Forecast

No Data

News

Comment

No Data

Company Overview More
Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. was incorporated in 2021 and is headquartered in New York, New York.
CEO: Meckler, Jeffrey A.
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...